NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Question: 1 / 1820

Alemtuzumab (Lemtrada) requires enrollment in what program due to safety concerns?

MEDWATCH Program

REMS Program

Alemtuzumab (Lemtrada) requires enrollment in the REMS (Risk Evaluation and Mitigation Strategy) Program due to safety concerns. The REMS program is a strategy to manage known or potential serious risks associated with a drug product and is required for certain medications with significant safety concerns. By enrolling in the REMS program, healthcare providers and patients are educated about these risks and how to minimize them, ensuring safe use of the medication. This program includes elements such as training, certification, dispensing restrictions, patient monitoring, and follow-up. The other options mentioned are not specifically designed to address safety concerns related to specific medications like the REMS program.

Get further explanation with Examzify DeepDiveBeta

Patient Assistance Program

SAFE Rx Program

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy